



WIENER LABORATORIOS S.A.I.C. - Riobamba 2944 - 2000 Rosario - Argentina  
Phone +54 (341) 432-9191/6 - Fax +54 (341) 432-5454/5555  
Internet: <http://www.wiener-lab.com.ar>

## Section 6 – Summary

FEB 12 2003

### 510(k) Summary

**"This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21CFR 807.92"**

**"The assigned 510(k) number is: K023992"**

#### Introduction

According to the requirements of 21 CFR 862.3240, the following information provides sufficient details to understand the basis of a determination of substantial equivalence.

#### 6-1 Submitter Name, Address, Contact

Wiener Laboratorios S.A.I.C.  
Riobamba 2944  
2000 – Rosario – Argentina  
Tel: 54 341 4329191  
Fax: 54 341 4851986  
Contact person: Viviana Cétola  
Date Prepared: September 02, 2002

#### 6-2 Device Name

Proprietary name: Wiener lab. Colinesterasa AA.  
Common name: Cholinesterase test system.  
Classification name: Colorimetry, Cholinesterase.  
Device Class I



**6-3 Predicate Device**

We claim substantial equivalence to the currently marketed SIGMA DIAGNOSTICS Cholinesterase (BTC) (Cat. 421-10).

**6-4 Device Description**

Kinetic Method.

The principle is based on the following reaction system:



The cholinesterase activity is determined by measuring the rate of absorbance change at 405 nm.

DTNB: 5,5'-Dithiobis-2-Nitrobenzoic Acid.

ChE: serum or plasma cholinesterase.

**6-5 Intended Use**

The WIENER LAB. Colinesterasa AA test system is a quantitative in vitro diagnostic device intended to be used in the quantitative determination of cholinesterase (an enzyme that catalyzes the hydrolysis of acetylcholine to choline) in human specimens, on both manual and automated systems. There are two principal types of cholinesterase in human tissues. True cholinesterase is present at nerve endings and in erythrocytes (red blood cells) but is not present in plasma. Pseudo cholinesterase is present in plasma and liver but is not present in erythrocytes. Measurements obtained by this device are used in the diagnosis and treatment of cholinesterase inhibition disorders (e.g., insecticide poisoning and succinylcholine poisoning).

**6-6 Equivalencies and Differences**

The WIENER LAB. Colinesterasa AA test system is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently marketed SIGMA DIAGNOSTICS Cholinesterase (BTC) test system.

The following table illustrates the similarities and differences between the WIENER LAB. Colinesterasa AA test system and the currently marketed SIGMA DIAGNOSTICS Cholinesterase (BTC) test system.

	Cholinesterase (BTC)	Colinesterasa AA
Intended Use	For the quantitative, kinetic determination of cholinesterase activity in serum at 405 nm.	Kinetic method at 405 nm for the determination of cholinesterase in serum or plasma.
Test Principle	<p>Kinetic Method.</p> <p>The principle is based on the following reaction system:</p> $\text{Butyrylthiocholine} + \text{H}_2\text{O} \xrightarrow{\text{Cholinesterase}} \text{Thiocholine} + \text{Butyrate}$ $\text{Thiocholine} + \text{DTNB} \longrightarrow \text{2-Nitro-5-Mercapto-benzoate}$ <p>The cholinesterase activity is determined by measuring the rate of absorbance change at 405 nm.</p> <p>DTNB: 5,5'-Dithiobis-2-Nitrobenzoic Acid. ChE: serum or plasma cholinesterase.</p>	
Reagents	Cholinesterase (BTC) Reagent: Butyrylthiocholine iodide – DTNB – Buffer.	Reagent 1: DTNB – Phosphate buffer. Reagent 2: Butyrylthiocholine. Diluent 1 and 2: aqueous solution.
Preparation of Working Reagent	Reconstitute Cholinesterase (BTC) Reagent with indicated volume of deionized water	Reconstitute each Reagent 1 and 2 vial with stated volume of Diluent 1 and 2 respectively.
Wavelength of Reading	405 nm	
Linearity	13000 U/l for a Sample/Reagent Ratio 1:300	17000 U/l
Continued on next page		

	Cholinesterase (BTC)	Colinesterasa AA
Expected values	3200 – 7700 U/l at 30°C	<p>Children, men and women over 40 years old: 5500 - 13400 U/l (37°C)</p> <p>Women between 16 - 39 years old, non pregnant and not ingesting oral contraceptives: 4400 - 11700 U/l (37°C)</p> <p>Women between 18 - 41 years old, pregnant or ingesting oral contraceptives: 3800 - 9500 U/l (37°C)</p>
Within-run precision	<p>Normal Level Serum: CV = 2.0%</p> <p>High Level Serum: CV = 1.8%</p>	<p>Normal Level Serum: CV = 1.41%</p> <p>High Level Serum: CV = 0.97%</p>
Total precision	<p>Normal Level Serum: CV = 4.2%</p> <p>High Level Serum: CV = 2.6%</p>	<p>Normal Level Serum: CV = 2.00%</p> <p>High Level Serum: CV = 1.97%</p>

---

**6-7 Conclusion** Above mentioned data show substantial equivalency to the predicate device.

---



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

FEB 12 2003

Dr, Viviana Cetola  
QC/QA Manager  
Weiner Laboratorios S.A.I.C.  
Riobamba 2944  
Rosario, Santa Fe  
Argentina 2000

Re: k023992  
Trade/Device Name: Wiener Lab. Colinesterasa AA  
Regulation Number: 21 CFR 862.3240  
Regulation Name: Cholinesterase test system  
Regulatory Class: Class I  
Product Code: DIH  
Dated: January 20, 2003  
Received: January 22, 2003

Dear Dr. Cetola:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and  
Radiological Health

Enclôsure

Page \_\_\_\_ of \_\_\_\_

510(k) Number (if known):

K023992


Device Name:

Wiener lab.Colinesterasa AA**Indications For Use:**

The "Wiener lab. Colinesterasa AA" test system is a quantitative in vitro diagnostic device intended to be used in the quantitative determination of cholinesterase (an enzyme that catalyzes the hydrolysis of acetylcholine to choline) in human serum or plasma, on both manual and automated systems. There are two principal types of cholinesterase in human tissues. True cholinesterase is present at nerve endings and in erythrocytes (red blood cells) but is not present in plasma. Pseudo cholinesterase is present in plasma and liver but is not present in erythrocytes. Measurements obtained by this device are used in the diagnosis and treatment of cholinesterase inhibition disorders (e.g., insecticide poisoning and succinylcholine poisoning).

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number

K023992Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐

(Optional Format 1-2-96)